Bold claim: fullerenes could simplify MRI contrast by enabling high-sensitivity targets, potentially transforming medical imaging as we know it. But here's where it gets controversial: this approach could redefine how clinicians diagnose and monitor disease, stirring debate over safety, practicality, and cost.
Magnetic resonance imaging (MRI) already plays a pivotal role in modern medicine, offering noninvasive, 3D views of the human body. Yet there’s always room to sharpen its sensitivity and specificity. One promising avenue is dynamic nuclear polarization (DNP), a technique that enhances MRI signals by priming target molecules to produce clearer images. Traditional DNP, however, relies on special crystalline materials and polarizing agents, requirements that can be challenging to implement in practice.
Researchers, including teams from the University of Tokyo, have demonstrated a novel use of fullerenes—also known as buckyballs—as polarizing agents for DNP. This breakthrough could enable targets to reach much higher polarization levels, yielding sharper MRI images with potentially broad medical applications.
To understand the idea, consider how MRI works. A strong magnetic field aligns the protons in water within the body. Radio waves disturb this alignment, and as protons realign, they emit signals that the MRI machine converts into images. The richness of the information depends on how well these signals can be polarized and detected. Conventional MRI is most effective with water-rich tissues, so expanding the detectable range requires augmenting the polarization of additional targets.
The team’s key finding is that specially designed fullerenes can boost polarization rates to about 14.2% in a disordered, glassy material. This is above the practical threshold (10%) for useful imaging in biological contexts, where polarized signals must endure long enough to be captured before decaying. The lead researchers, including Professor Nobuhiro Yanai, noted that these fullerenes—referred to as trans-3a isomers—are engineered to minimize rotational movement, helping maintain polarization once excited.
The practical workflow involves polarizing the targets outside the body, dissolving the sample, and removing the fullerene-containing material before any potential clinical use. This approach—triplet-DNP—eliminates the need for liquid helium cooling, allowing the process to run on more affordable equipment. It also opens the door to polarizing diagnostic probes like pyruvate or certain anticancer drugs that standard MRI cannot detect.
Looking ahead, the researchers aim to develop biocompatible matrices that can safely host these hyperpolarized molecules for in vivo use. Their plan includes validating high-sensitivity MRI in animal models, followed by clinical trials, with the hopeful timeline of bringing this technology to patient care within roughly 10 to 20 years.
Source:
Sakamoto, K., et al. (2025). Substituted Fullerenes for Enhanced Optical Nuclear Hyperpolarization in Random Orientations. Nature Communications. doi: 10.1038/s41467-025-66211-y.
While the potential benefits are exciting, this work also raises questions about safety, scalability, and cost. Should more research funds flow into fullerenes-based DNP, and what regulatory hurdles must be cleared before clinical use? How might this technology affect patient access and the economics of MRI-based diagnostics? Share your thoughts in the comments: is this a groundbreaking leap forward or a controversial detour from established imaging practices?
